Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

The role of mesenchymal stromal cells in spinal cord injury, regenerative medicine and possible clinical applications.

Forostyak S., Jendelova P., Sykova E.

Clinical Trial on Spinal Cord Injury, Immune Modulation, published in Biochimie (2013) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Biochimie (2013)
Country
France
Reported sample size
—
Source database
PubMed
PMID
23994163
DOI
10.1016/j.biochi.2013.08.004

Abstract (original English)

Diseases of the central nervous system still remain among the most challenging pathologies known to mankind, having no or limited therapeutic possibilities and a very pessimistic prognosis. Advances in stem cell biology in the last decade have shown that stem cells might provide an inexhaustible source of neurons and glia as well as exerting a neuroprotective effect on the host tissue, thus opening new horizons for tissue engineering and regenerative medicine. Here, we discuss the progress made in the cell-based therapy of spinal cord injury. An emphasis has been placed on the application of adult mesenchymal stromal cells (MSCs). We then review the latest and most significant results from in vitro and in vivo research focusing on the regenerative/neuroprotective properties of MSCs. We also attempt to correlate the effect of MSCs with the pathological events that are taking place in the nervous tissue after SCI. Finally, we discuss the results from preclinical and clinical trials involving different routes of MSC application into patients with neurological disorders of the spinal cord.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsCell- and Tissue-Based TherapyClinical Trials as TopicHumansInflammationMesenchymal Stem CellsNerve RegenerationRegenerative MedicineSpinal Cord Injuries

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research